INTERACTION OF HIV MEDICATIONS WITH OPIATE THERAPY MEDICATIONS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的目的是测试丁丙诺啡-纳洛酮和治疗HIV疾病的药物的相互作用。如果参与者对海洛因或处方药成瘾，并且目前未接受药物滥用治疗，则有资格参加本研究。研究受试者必须在参加研究前接受Suboxone治疗至少2周，这有助于预防戒断症状。预计入组人数为70人，HIV药物将服用5天。 本研究将要求RS作为门诊患者参加，并入院进行血液和尿液采样（两个阶段各1-2晚）。斯普斯卡共和国还必须同意每天到诊所接受药物治疗和健康检查，星期日除外。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is test the interactions of buprenorphine-naloxone, and medications to treat HIV disease. The participants will be eligible for this study if they have an addiction to heroin or prescription medications and are not currently receiving substance abuse treatment. The research subject must be taking Suboxone therapy, which helps prevent withdrawal symptoms, for at least 2 weeks before joining the study. The anticipated enrollment is 70 and the HIV drugs will be taken for 5 days. This study will require that RS participate as an outpatient and be admitted to the hospital for blood and urine sampling sessions (1-2 nights for each of the two sessions). The RS must also agree to daily visits to the clinic, except for Sundays, to take medication and have a health examination.